These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 25872118)

  • 1. Glucagon-like peptides 1 and 2: intestinal hormones implicated in the pathophysiology of mucositis.
    Kissow H
    Curr Opin Support Palliat Care; 2015 Jun; 9(2):196-202. PubMed ID: 25872118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucagon-like peptide-1 as a treatment for chemotherapy-induced mucositis.
    Kissow H; Hartmann B; Holst JJ; Poulsen SS
    Gut; 2013 Dec; 62(12):1724-33. PubMed ID: 23086829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endogenous glucagon-like peptide- 1 and 2 are essential for regeneration after acute intestinal injury in mice.
    Hytting-Andreasen R; Balk-Møller E; Hartmann B; Pedersen J; Windeløv JA; Holst JJ; Kissow H
    PLoS One; 2018; 13(6):e0198046. PubMed ID: 29864142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucagon-like peptides 1 and 2 in health and disease: a review.
    Marathe CS; Rayner CK; Jones KL; Horowitz M
    Peptides; 2013 Jun; 44():75-86. PubMed ID: 23523778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exogenous glucagon-like peptide-2 (GLP-2) prevents chemotherapy-induced mucositis in rat small intestine.
    Kissow H; Viby NE; Hartmann B; Holst JJ; Timm M; Thim L; Poulsen SS
    Cancer Chemother Pharmacol; 2012 Jul; 70(1):39-48. PubMed ID: 22729158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Irinotecan-induced mucositis: the interactions and potential role of GLP-2 analogues.
    Mayo BJ; Stringer AM; Bowen JM; Bateman EH; Keefe DM
    Cancer Chemother Pharmacol; 2017 Feb; 79(2):233-249. PubMed ID: 27770239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor.
    Boushey RP; Yusta B; Drucker DJ
    Cancer Res; 2001 Jan; 61(2):687-93. PubMed ID: 11212269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matrix metalloproteinases: key regulators in the pathogenesis of chemotherapy-induced mucositis?
    Al-Dasooqi N; Gibson RJ; Bowen JM; Keefe DM
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):1-9. PubMed ID: 19305997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review article: a comparison of glucagon-like peptides 1 and 2.
    Janssen P; Rotondo A; Mulé F; Tack J
    Aliment Pharmacol Ther; 2013 Jan; 37(1):18-36. PubMed ID: 23121085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Glucagon-like peptides--synthesis, biological actions and some clinical implications].
    Otto Buczkowska E; Dworzecki T
    Przegl Lek; 2004; 61(9):947-50. PubMed ID: 15803906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The therapeutic potential of targeting the glucagon-like peptide-2 receptor in gastrointestinal disease.
    Hornby PJ; Moore BA
    Expert Opin Ther Targets; 2011 May; 15(5):637-46. PubMed ID: 21314232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucagon-like peptide 2 improves intestinal wound healing through induction of epithelial cell migration in vitro-evidence for a TGF--beta-mediated effect.
    Bulut K; Meier JJ; Ansorge N; Felderbauer P; Schmitz F; Hoffmann P; Schmidt WE; Gallwitz B
    Regul Pept; 2004 Sep; 121(1-3):137-43. PubMed ID: 15256284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis.
    Drucker DJ
    Mol Endocrinol; 2003 Feb; 17(2):161-71. PubMed ID: 12554744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute effects of continuous infusions of glucagon-like peptide (GLP)-1, GLP-2 and the combination (GLP-1+GLP-2) on intestinal absorption in short bowel syndrome (SBS) patients. A placebo-controlled study.
    Madsen KB; Askov-Hansen C; Naimi RM; Brandt CF; Hartmann B; Holst JJ; Mortensen PB; Jeppesen PB
    Regul Pept; 2013 Jun; 184():30-9. PubMed ID: 23511332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastrointestinal defense mechanisms.
    Said H; Kaunitz JD
    Curr Opin Gastroenterol; 2016 Nov; 32(6):461-466. PubMed ID: 27653163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucagon-like peptide-1: glucose homeostasis and beyond.
    Cho YM; Fujita Y; Kieffer TJ
    Annu Rev Physiol; 2014; 76():535-59. PubMed ID: 24245943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The glucagon-like peptides: pleiotropic regulators of nutrient homeostasis.
    Brubaker PL
    Ann N Y Acad Sci; 2006 Jul; 1070():10-26. PubMed ID: 16888147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct and indirect mechanisms regulating secretion of glucagon-like peptide-1 and glucagon-like peptide-2.
    Brubaker PL; Anini Y
    Can J Physiol Pharmacol; 2003 Nov; 81(11):1005-12. PubMed ID: 14719035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gut Peptides Are Novel Regulators of Intestinal Lipoprotein Secretion: Experimental and Pharmacological Manipulation of Lipoprotein Metabolism.
    Xiao C; Dash S; Morgantini C; Adeli K; Lewis GF
    Diabetes; 2015 Jul; 64(7):2310-8. PubMed ID: 26106188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy-induced mucositis: the role of gastrointestinal microflora and mucins in the luminal environment.
    Stringer AM; Gibson RJ; Bowen JM; Logan RM; Yeoh AS; Keefe DM
    J Support Oncol; 2007 Jun; 5(6):259-67. PubMed ID: 17624050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.